Assignee
ZYMEWORKS INC
CA·45 granted patents·31 pending applications·335 citations·filing 2006–2022
Top patents by PatentIndex Score
76 records- 0197US9499634B2Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cellsZYMEWORKS INC·Filed 2013·Granted Nov 22, 2016·50 cites·30 claims
- 0296US10000576B1Bispecific antigen-binding constructs targeting HER2ZYMEWORKS INC·Filed 2018·Granted Jun 19, 2018·23 cites·30 claims
- 0396US9574010B2Stable heterodimeric antibody design with mutations in the Fc domainZYMEWORKS INC·Filed 2012·Granted Feb 21, 2017·48 cites·79 claims
- 0495US10457742B2Stable heterodimeric antibody design with mutations in the Fc domainZYMEWORKS INC·Filed 2017·Granted Oct 29, 2019·17 cites·32 claims
- 0595US9522876B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS INC·Filed 2014·Granted Dec 20, 2016·19 cites·48 claims
- 0692US9914785B2Engineered immunoglobulin heavy chain-light chain pairs and uses thereofZYMEWORKS INC·Filed 2013·Granted Mar 13, 2018·17 cites·15 claims
- 0792US9879086B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS INC·Filed 2015·Granted Jan 30, 2018·11 cites·90 claims
- 0891US11286293B2Engineered immunoglobulin heavy chain-light chain pairs and uses thereofZYMEWORKS INC·Filed 2018·Granted Mar 29, 2022·6 cites·25 claims
- 0991US11161915B2Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereofZYMEWORKS INC·Filed 2016·Granted Nov 2, 2021·7 cites·26 claims
- 1091US9388231B2Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2013·Granted Jul 12, 2016·16 cites·38 claims
- 1190US11306156B2Modified antigen binding polypeptide constructs and uses thereofZYMEWORKS INC·Filed 2015·Granted Apr 19, 2022·7 cites·37 claims
- 1290US11078296B2Engineered immunoglobulin heavy chain-light chain pairs and uses thereofZYMEWORKS INC·Filed 2018·Granted Aug 3, 2021·5 cites·12 claims
- 1390US10077298B2Engineered immunoglobulin heavy chain-light chain pairs and uses thereofZYMEWORKS INC·Filed 2013·Granted Sep 18, 2018·15 cites·22 claims
- 1490US9988460B2Crystal structures of heterodimeric Fc domainsZYMEWORKS INC·Filed 2017·Granted Jun 5, 2018·8 cites·15 claims
- 1589US11325981B2Bispecific antigen-binding constructs targeting Her2ZYMEWORKS INC·Filed 2018·Granted May 10, 2022·2 cites·19 claims
- 1689US10947319B2Bispecific antigen-binding constructs targeting HER2ZYMEWORKS INC·Filed 2014·Granted Mar 16, 2021·5 cites·18 claims
- 1789US10155803B2Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2016·Granted Dec 18, 2018·3 cites·27 claims
- 1889US9732155B2Crystal structures of heterodimeric Fc domainsZYMEWORKS INC·Filed 2013·Granted Aug 15, 2017·12 cites·15 claims
- 1988US10875931B2Stable heterodimeric antibody design with mutations in the Fc domainZYMEWORKS INC·Filed 2017·Granted Dec 29, 2020·4 cites·8 claims
- 2087US11147886B2Drug-conjugated bi-specific antigen-binding constructsZYMEWORKS INC·Filed 2016·Granted Oct 19, 2021·3 cites·15 claims
- 2187US11000598B2Anti-HER2 biparatopic antibody-drug conjugates and methods of useZYMEWORKS INC·Filed 2019·Granted May 11, 2021·5 cites·17 claims
- 2285US11028182B2Antigen-binding constructs targeting HER2ZYMEWORKS INC·Filed 2016·Granted Jun 8, 2021·2 cites·28 claims
- 2385US9771573B2Methods of quantitating heavy and light chain polypeptide pairsZYMEWORKS INC·Filed 2013·Granted Sep 26, 2017·8 cites·36 claims
- 2483US10201614B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS INC·Filed 2014·Granted Feb 12, 2019·3 cites·38 claims
- 2581US10711051B2Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2018·Granted Jul 14, 2020·1 cites·21 claims
- 2680US11152081B2Methods for determining correlated residues in a protein or other biopolymer using molecular dynamicsZYMEWORKS INC·Filed 2016·Granted Oct 19, 2021·3 cites·7 claims
- 2780US10414822B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS INC·Filed 2018·Granted Sep 17, 2019·2 cites·34 claims
- 2879US10450378B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS INC·Filed 2015·Granted Oct 22, 2019·2 cites·61 claims
- 2978US10358479B2Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2016·Granted Jul 23, 2019·2 cites·24 claims
- 3077US10255409B2Systems and methods for in silico evaluation of polymersZYMEWORKS INC·Filed 2014·Granted Apr 9, 2019·9 cites·27 claims
- 3176US11208497B2Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereofZYMEWORKS INC·Filed 2014·Granted Dec 28, 2021·2 cites·39 claims
- 3276US11098105B2Heteromultimers with reduced or silenced effector functionZYMEWORKS INC·Filed 2014·Granted Aug 24, 2021·2 cites·16 claims
- 3375US10508154B2Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cellsZYMEWORKS INC·Filed 2016·Granted Dec 17, 2019·1 cites·37 claims
- 3474US11560422B2Sulfonamide-containing linkage systems for drug conjugatesZYMEWORKS INC·Filed 2014·Granted Jan 24, 2023·1 cites·38 claims
- 3573US10273303B2Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereofZYMEWORKS INC·Filed 2014·Granted Apr 30, 2019·2 cites·21 claims
- 3673US10239951B2Bispecific HER2 and HER3 antigen binding constructsZYMEWORKS INC·Filed 2014·Granted Mar 26, 2019·2 cites·20 claims
- 3771US7769573B2System and method for modeling interactionsZYMEWORKS INC·Filed 2006·Granted Aug 3, 2010·9 cites·19 claims
- 3871US2021317212A1Bispecific Asymmetric Heterodimers Comprising Anti-CD3 ConstructsZYMEWORKS INC·Filed 2021·Application pending·0 cites
- 3969US2021277150A1STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAINZYMEWORKS INC·Filed 2020·Application pending·0 cites
- 4068US11248037B2Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2019·Granted Feb 15, 2022·0 cites·36 claims
- 4168US2021009659A1Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2020·Application pending·0 cites
- 4265US2020087414A1STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAINZYMEWORKS INC·Filed 2019·Application pending·0 cites
- 4361US2021269553A1Methods using monovalent antigen binding constructs targeting her2ZYMEWORKS INC·Filed 2020·Application pending·0 cites
- 4461US2019248897A1Bispecific Asymmetric Heterodimers Comprising Anti-CD3 ConstructsZYMEWORKS INC·Filed 2019·Application pending·0 cites
- 4561US2021260210A1Anti-her2 biparatopic antibody-drug conjugates and methods of useZYMEWORKS INC·Filed 2019·Application pending·0 cites
- 4659US2014154253A1Bispecific Asymmetric Heterodimers Comprising Anti-CD3 ConstructsZYMEWORKS INC·Filed 2013·Application pending·0 cites
- 4758US2026042847A1Cysteine engineered antibody constructs, conjugates and methods of useZYMEWORKS INC·Filed 2022·Application pending·0 cites
- 4854US2023331809A1Fusion proteins comprising a ligand-receptor pair and a biologically functional proteinZYMEWORKS INC·Filed 2021·Application pending·0 cites
- 4954US2016114057A1Modular protein drug conjugate therapeuticZYMEWORKS INC·Filed 2014·Application pending·0 cites
- 5054US2013336973A1Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc DomainZYMEWORKS INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 76 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →